Marshall Wace LLP Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marshall Wace LLP boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 632.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 207,114 shares of the company's stock after buying an additional 178,841 shares during the period. Marshall Wace LLP owned approximately 0.25% of IDEXX Laboratories worth $85,629,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after acquiring an additional 37,734 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after purchasing an additional 34,305 shares during the last quarter. Invesco Ltd. lifted its position in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after buying an additional 74,324 shares during the last quarter. Norges Bank acquired a new stake in IDEXX Laboratories in the fourth quarter valued at about $412,258,000. Finally, American Century Companies Inc. grew its position in IDEXX Laboratories by 30.9% in the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company's stock valued at $334,810,000 after acquiring an additional 191,385 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average price target of $523.75.

IDEXX Laboratories Trading Up 3.4 %

IDEXX Laboratories stock traded up $13.67 during trading hours on Tuesday, reaching $420.32. 216,268 shares of the company's stock were exchanged, compared to its average volume of 623,558. The firm has a market capitalization of $34.06 billion, a PE ratio of 39.40, a PEG ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm's 50 day simple moving average is $421.36 and its 200 day simple moving average is $429.98. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.